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ABSTRACT
Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, 
resistance remains a challenge. We have previously shown that ADAM17 plays a 
key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside 
ADAM17, ADAM10 is the other well characterized ADAM protease responsible for HER 
ligand shedding. Therefore, we studied the role of ADAM10 in relation to trastuzumab 
treatment and resistance in HER2 positive breast cancer. ADAM10 expression was 
assessed in HER2 positive breast cancer cell lines and xenograft mice treated with 
trastuzumab. Trastuzumab treatment increased ADAM10 levels in HER2 positive breast 
cancer cells (p≤0.001 in BT474; p≤0.01 in SKBR3) and in vivo (p≤0.0001) compared 
to control, correlating with a decrease in PKB phosphorylation. ADAM10 inhibition or 
knockdown enhanced trastuzumab response in naïve and trastuzumab resistant breast 
cancer cells. Trastuzumab monotherapy upregulated ADAM10 (p≤0.05); and higher 
pre-treatment ADAM10 levels correlated with decreased clinical response (p≤0.05) at 
day 21 in HER2 positive breast cancer patients undergoing a trastuzumab treatment 
window study. Higher ADAM10 levels correlated with poorer relapse-free survival 
(p≤0.01) in a cohort of HER2 positive breast cancer patients. Our studies implicate 
a role of ADAM10 in acquired resistance to trastuzumab and establish ADAM10 as a 
therapeutic target and a potential biomarker for HER2 positive breast cancer patients.
INTRODUCTION
The HER (human epidermal growth factor receptor) 
family of receptor tyrosine kinases includes four receptors: 
EGFR, HER2, HER3, and HER4. Several ligands bind to 
these receptors including heregulin and betacellulin [1]. 
Ligand binding facilitates homo- or heterodimerization 
[2], which triggers phosphorylation [3] and activates 
downstream signalling via the PI3K/AKT and the MAPK 
pathway [1, 4]. Amplification and overexpression of 
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HER2 occur in about 10-20% of all breast cancer cases, 
correlating with poorer outcome [5, 6]. Trastuzumab 
(Herceptin), a humanized monoclonal antibody 
recognizing HER2 [7, 8], is effective in the treatment 
of HER2 overexpressing breast cancer in adjuvant and 
metastatic settings [9-12]. However, the response rate 
to trastuzumab monotherapy is less than 30% [13] and 
primary or acquired resistance remains a challenge. 
Therefore, it is of utmost importance to find strategies to 
overcome resistance and to establish biomarkers to predict 
response and resistance to trastuzumab.
Protein shedding via various ADAMs (a disintegrin 
and metalloproteinase) is important for cell fate 
determination, migration, and proliferation [14]. ADAM10 
has been implicated in the cleavage of a number of proteins 
such as Ephrins [15], N-cadherin [16], E-cadherin [17], 
Notch receptor and its ligand Delta 1 [18]. ADAM10 is 
also involved in the shedding of EGF and betacellulin [19]
as well as the HER2 receptor [20]. The role of ADAM10 
overexpression was reported in several malignancies such 
as gastric [21], prostate [22], and liver [23] although its 
clinical significance in breast cancer is unknown.
We have previously shown that ADAM17 mediates 
HER receptor activation during trastuzumab treatment 
[24]. Since ADAM17 and ADAM10 are the two best 
characterized ADAM proteases responsible for HER 
ligand shedding [14], we investigated the role of ADAM10 
in relation to trastuzumab treatment and resistance in 
HER2 positive breast cell lines, in vivo and in HER2 
positive breast cancer patients.
RESULTS
Trastuzumab treatment increases ADAM10 levels 
in vitro and in vivo
To assess the effect of trastuzumab treatment on 
ADAM10 expression, BT474 and SKBR3 cells were 
treated with two doses of trastuzumab for 24 hours. 
ADAM10 mRNA levels were increased in a dose-
dependent manner: a 3.6–fold increase in BT474 cells and 
a 2.5-fold in SKBR3 after 40µg/ml trastuzumab treatment, 
compared to untreated control (figure 1A, left upper and 
lower panels, both cell lines, n=3, p≤0.01). ADAM10 
protein levels were increased by 7–fold in BT474 and 
5–fold in SKBR3 cells (figure 1A, middle and right 
panels, n=3 each, p≤0.01). The upregulation of ADAM10 
coincided with an increase of the ligand betacellulin, 
which is shed by this protease, in the media of trastuzumab 
treated cells in comparison to control (figure 1B, n=3, 
p≤0.05). 
To assess the relevance of this observation in an 
in vivo model, tissue samples from BT474 xenograft 
models treated with trastuzumab or vehicle [30] were 
stained for ADAM10 expression. The IHC staining was 
first optimized and was specific (figure S1A). ADAM10 
expression was increased in trastuzumab treated xenograft 
samples (mean IRS 10.6, 95% CI 9.7-11.5) compared 
to control (mean IRS 6.2, 95% CI 5.0-7.3; ntotal=30, 
p≤0.0001) (figure 1C). Therefore, trastuzumab treatment 
led to an upregulation of ADAM10 protein levels in vitro 
and in vivo. 
Figure 1: Treatment with trastuzumab leads to an 
increase of ADAM10 levels in vitro and in vivo (A) 
BT474 and SKBR3 cells were treated for 24h with the 
indicated doses of trastuzumab before ADAM10 mRNA 
and protein levels were assessed. The relative protein 
levels from the semi-quantification of three western blots are 
shown. (B) BT474 and SKBR3 cells were treated with 40μg/
ml trastuzumab in serum-free media and betacellulin levels in 
the media were assessed in triplicate using ELISA after 24h. (C) 
Paraffin-embedded tumor slides from xenograft mice bearing 
BT474 tumors treated with trastuzumab (50 mg/kg loading dose 
and 25 mg/kg maintenance dose administered intraperitoneally 
twice a week) or saline (control) for a total of 5 doses [30] were 
stained for ADAM10 expression by IHC before being scored 
using IRS. Graphs show means ± SD. 
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PKB inhibition leads to an upregulation of 
ADAM10 levels in vitro and in vivo
We previously established that the PKB inhibition 
by trastuzumab [31] increases ADAM17 levels [24]. Thus, 
we investigated this mechanism in relation to ADAM10. 
Both trastuzumab and an allosteric AKT/PKB inhibitor 
could decrease PKB phosphorylation (figure 2A). In a 
dose escalation study using trastuzumab, the decrease of 
PKB phosphorylation occurred concomitantly with the 
increase of ADAM10 protein level. The increase was non-
linear although the highest dose of trastuzumab yielded 
the highest increase of ADAM10 level (figure 2B). To 
further assess the effect of PKB inhibition on ADAM10 
expression, BT474 and SKBR3 cells were treated with the 
AKT/PKB inhibitor. ADAM10 mRNA level was increased 
in a time-dependent manner in both cell lines (figure 2C, 
upper and lower panels, n=3, p≤0.01 at 24h). ADAM10 
protein levels were increased at 1h (figure 2C, upper and 
lower panels, n=3, p≤0.01). The increase was also seen 
in BT474 xenograft models treated with an AKT/PKB 
inhibitor (mean IRS 10.8, 95% CI 6.8-14.8) compared to 
control (mean IRS 2.8, 95% CI 1.2-4.3; ntotal=8, p≤0.001) 
(figure 2D). We showed that the increase in ADAM10 is 
related to the decrease in PKB phosphorylation by using 
other agents targeting this protein (neratinib, a TKI, and a 
Figure 2: The upregulation of ADAM10 is correlated with AKT inhibition in vitro and in vivo (A) SKBR3 cells were 
treated with an allosteric AKT/PKB inhibitor (2.5µM) or trastuzumab for the indicated durations and (B) with increasing 
doses of trastuzumab for 24h before western blotting. (C) BT474 and SKBR3 cells were treated with an AKT/PKB inhibitor (2.5µM) 
before ADAM10 mRNA and protein levels were assessed. The relative protein levels from the semi-quantification of three western blots 
are shown. (D) Paraffin-embedded tumor slides from xenograft mice bearing BT474 tumors treated with an AKT/PKB inhibitor (AKTi-1/2, 
50mg/kg ip) or control for 4h were stained for ADAM10 expression by IHC and scored using IRS. (E) SKBR3 cells were treated with 1nM 
neratinib, 200nM PI3K inhibitor, 2.5µM AKT/PKB inhibitor or 40µg/ml trastuzumab for 24h before western blot. Graphs show means ± 
SD. 
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PI3K inhibitor) which also induced ADAM10 protein at 
24h of treatment (figure 2E). Collectively, this suggests 
that PKB inhibition by trastuzumab induces ADAM10 
upregulation.
ADAM10 inhibition decreases basal and 
trastuzumab induced activation of HER receptors 
and enhances trastuzumab response
The upregulation of ADAM10 by trastuzumab 
treatment at 24h in both cell lines occurred with an 
increase of betacellulin (ligand for EGFR and HER4) in 
the media (figure 3A, n=3, p≤0.001, S1B), correlating with 
enhanced phosphorylation of EGFR and HER4 receptors 
and their preferential dimerization partner HER2 (figures 
3B left and right panels, S1D). 
We therefore proceeded to assess the effect of 
an ADAM10 inhibitor (ADAM10i) in HER2 positive 
breast cancer cells. Treatment of SKBR3 and BT474 
cells with INCB8765 (specific ADAM10 inhibitor) for 
24h led to a decrease in the level of basal (figures 3A, 
dmso vs. ADAM10i, n=3, p≤0.05, S1B) and trastuzumab 
Figure 3: ADAM10 inhibition decreases basal and trastuzumab induced HER activation and enhances trastuzumab 
response SKBR3 cells were treated with 40µg/ml trastuzumab, 5µM ADAM10 inhibitor INCB8765 (ADAM10i), or their 
combination in serum-free media as indicated for 24h. (A) Betacellulin levels in the media were assessed in triplicate using ELISA; 
and (B) cell lysates were used for western blot and quantification of three blots is shown (phosphorylated proteins relative to the respective 
total proteins). (C) Left, BT474 cells were treated with 40µg/ml trastuzumab, 5µM ADAM10 inhibitor INCB8765 (ADAM10i), or their 
combination for 5 days in serum-reduced media. Camptothecin (6µM) was used as positive control. Cells were stained for Annexin V and 
the percentage of positive cells was assessed by FACS analysis. Right, BT474 cells were treated as indicated in serum-reduced media for 
72h before western blot. (D) SKBR3 cells were treated as in (C) before cells were re-plated in duplicate and left for colony-formation for 
12 days. Cells were then stained and counted. (E) SKBR3 cells were seeded in triplicate and treated as in (C) before MTT assay analysis. 
Graphs show means ± SD. 
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Figure 4: ADAM10 knockdown decreases cell viability and enhances trastuzumab response by inhibiting the activation 
of HER receptors (A) In SKBR3 cells, ADAM10 was knocked down using two siRNAs (20nM) or their combination before 
western blotting after 72h. Quantification of three blots is shown (phosphorylated proteins relative to the respective total proteins). (B) 
BT474 cells were transfected with 20nM of siRNA against ADAM10 for 72h and camptothecin (6µM) was used as positive control. Cells 
were stained for Annexin V and the percentage of positive cells was assessed by FACS analysis. (C) SKBR3 cells were transfected as in (B) 
before cells were re-plated in duplicate and left for colony-formation for 12 days. (D) In cell counting assays, SKBR3 cells transfected as in 
(B) were seeded in triplicate and treated the next day with 40µg/ml trastuzumab as indicated for 5 days. (E) In SKBR3 cells, ADAM10 was 
knocked down and the cells were co-stimulated with 50ng/ml betacellulin as indicated for 5 days before cell counting experiments (left) or 
for 72h before western blot analysis for the indicated proteins (F). Graphs show means ± SD. 
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induced betacellulin secretion in the media (figures 3A, 
trastuzumab vs. trastuzumab + ADAM10i, n=3, p≤0.0001, 
S1B). ADAM10i also decreased cleavage of HER2, 
another substrate of ADAM10 (figure S1C), as reported 
previously (20).
In addition, ADAM10i decreased the basal and 
trastuzumab induced activation of EGFR, HER4, and 
HER2 in both cell lines (figures 3B, S1C). Although 
ADAM10 does not shed HER3 ligands (neuregulins), 
HER3 activation could be affected by dimerization with 
these receptors. ADAM10i alone did not have much effect 
on HER3 phosphorylation; however, it was additive to 
trastuzumab in decreasing HER3 activation (figure S1E). 
ADAM10i and trastuzumab effects on apoptosis and 
proliferation were also assessed. Trastuzumab treatment 
did not enhance apoptosis, as shown by Annexin V staining 
(figure 3C, left panel), although there was an increased 
cleaved caspase 7 expression (figures 3C, right panel, S1F) 
and a decrease in colony formation (figure 3D, IgG vs. 
trastuzumab, n=3, p≤0.001). However, the combination of 
trastuzumab with ADAM10i enhanced apoptosis (figures 
3C, n=3, p≤0.05, S1F) and inhibited proliferation to a 
greater extent than trastuzumab treatment alone (figure 
3D, n=3, p≤0.05). ADAM10i also decreased cell numbers 
and enhanced trastuzumab response (figures 3E, n=3, 
p≤0.05, S1G) in comparison to control. This suggested an 
additive effect of ADAM10i and trastuzumab. 
ADAM10 knockdown decreases activation of 
HER receptors but the effect is counteracted by 
exogenous ligand stimulation 
To further prove the role of ADAM10, we 
silenced ADAM10 using two different siRNAs (and a 
combination). The knockdown was first optimized and 
ADAM17 levels were not affected (figure S2A and B). 
ADAM10 knockdown decreased the phosphorylation 
of all HER receptors and the downstream pathways in 
comparison to control (figures 4A, left and right panels, 
n=3, S2C, 4E), fortifying the ADAM10 inhibitor results 
above. It also enhanced apoptosis (figure 4B, n=3, 
p≤0.001) and decreased colony formation (figure 4C, 
n=3, p≤0.0001) in comparison to control. Furthermore, 
ADAM10 knockdown enhanced response to trastuzumab 
treatment in both cell lines (figures 4D, n=3, p≤0.01, S2D). 
However, the addition of exogenous betacellulin reversed 
the inhibitory effect of ADAM10 knockdown on the 
activation of HER receptors (EGFR, HER2, and HER4) 
and the downstream pathways, which correlated with an 
increase in cell proliferation (measured by cell number) 
compared to ADAM10 knockdown alone (figure 4E). 
This is not surprising since ADAM10 knockdown effect 
on the endogenous release of HER ligands and should 
not have an effect on the exogenous ligand stimulation. 
HER3 phosphorylation was not recovered by the addition 
of exogenous betacellulin since it is not a HER3 ligand. 
These results confirm the role of ADAM10 in the shedding 
of endogenous HER ligands in HER2 positive breast 
Figure 5: ADAM10 and betacellulin levels 
are increased in acquired trastuzumab 
resistant cells compared to naïve cells 
Resistant cells were continuously treated with 
40µg/ml trastuzumab. (A) ADAM10 mRNA and 
protein levels of naïve and acquired trastuzumab 
resistant BT474 and SKBR3 cells were assessed. 
A representative blot and the semi-quantification of 
three blots are shown. (B) The naïve and acquired 
trastuzumab resistant BT474 and SKBR3 cells 
were seeded and the media was replaced the next 
day by serum-free media for 24h before ELISA. (C) 
ADAM10 was knocked down in resistant SKBR3 
cells and the level of betacellulin in the media was 
measured by ELISA. Graphs show means ± SD. 
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cancer cells. 
ADAM10 upregulation occurs in acquired 
trastuzumab resistance and resistant cells are 
sensitive to ADAM10 inhibition or knockdown
In view of the upregulation of ADAM10 during 
trastuzumab treatment in naïve cells, we hypothesized that 
ADAM10 might be implicated in acquired trastuzumab 
resistance. ADAM10 mRNA and protein levels were 
increased in the resistant cells compared to parental cells 
(figure 5A, each n=3, p≤0.05). Moreover, betacellulin 
levels in the media of resistant cells were also increased 
(figure 5B, n=3, p≤0.05). ADAM10 knockdown 
decreased the level of betacellulin in the media of SKBR3 
resistant cells (figure 5C). In addition, 24h treatment 
with ADAM10i (figures 6A; S3A) and ADAM10 
knockdown (figures 6B; S3B) decreased HER member 
phosphorylation and downstream pathway activation 
in trastuzumab resistant cells. ADAM10 inhibition 
increased the percentage of apoptotic cells (figure 6C, 
n=3, p ≤ 0.01) and decreased the number of colonies of 
trastuzumab resistant cells (figure 6D, n=3, p≤0.01) in 
comparison to control. However, the effect of ADAM10 
knockdown could be counteracted by the addition of 
exogenous betacellulin in the resistant cells, similar to the 
result in naïve cells (figure S3C). Although withdrawal of 
trastuzumab from the resistant cells led to an enhanced 
proliferation (n=3, p≤0.01), ADAM10 inhibition or 
knockdown reduced cell numbers compared to control 
and this effect was independent of trastuzumab treatment 
in both resistant cell lines (figure 6E; S3D, left and right 
panels). 
Comparing ADAM10, ADAM17 and ADAM10/17 
inhibition in HER2 positive breast cancer cells
We have shown the role of ADAM10 inhibition and 
knockdown in naïve and resistant HER2 positive breast 
cancer cells. Previously, we established that ADAM17 
inhibition also had an additive effect with trastuzumab 
treatment [24]. Therefore, we assessed whether a dual 
inhibition of ADAM10/17 would be superior to inhibition 
of either ADAM10 or ADAM17 alone. Although all 
Figure 6: ADAM10 inhibition or knockdown decreases activation of HER receptors and cell viability in trastuzumab 
resistant cell lines All resistant cells were continuously treated with 40μg/ml trastuzumab unless otherwise stated. (A) Resistant 
SKBR3 cells were treated with 5µM ADAM10 inhibitor INCB8765 (ADAM10i) for 24h in serum-free media or (B) were transfected with 
20nM of siRNAs against ADAM10 for 72h before western blotting and quantification of three blots is shown next to the respective blot 
(phosphorylated proteins relative to the respective total proteins). (C) For FACS analysis, resistant BT474 cells were treated with 5µM 
ADAM10 inhibitor INCB8765 (ADAM10i) in serum-reduced media for 5 days. Camptothecin (6µM) was used as positive control. Cells 
were stained for Annexin V and percentage of positive cells analysed by FACS. (D) For the clonogenic assay, resistant SKBR3 cells were 
treated as in (C) and re-plated in duplicate for colony-formation for 12 days. (E) For cell counting studies, trastuzumab was withdrawn 
overnight from resistant SKBR3 cell lines. For the “withdrawal group”, trastuzumab remained withdrawn whereas the “continuous group” 
was co-treated with 40µg/ml trastuzumab. Both groups were treated in as in (C), or were transfected with 20nM of specific siRNAs against 
ADAM10 for 5 days (right panel). (F) BT474 and SKBR3 cells were treated in triplicate with 40μg/ml trastuzumab, 5µM of the ADAM10 
inhibitor INCB8765 (ADAM10i), the ADAM17 inhibitor INCB4298 (ADAM17i), the ADAM10/17 inhibitor INCB3619 (ADAM10/17i), 
or their combination for 5 days before cell counting. (G) BT474 resistant cells were treated as in (F) with continuous 40μg/ml trastuzumab 
for 5 days before cell counting. Graphs represent data from three independent experiments and show means ± SD. 
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inhibitors enhanced trastuzumab response in SKBR3 
and BT474 cells, we found no statistically significant 
difference in cell viability between the combinations of 
trastuzumab with either the single inhibitors or the dual 
one (figure 6F, left and right panels). However, in BT474 
resistant cells, ADAM10 inhibition decreased cell count 
more than ADAM17 inhibition and dual inhibition was 
superior to either inhibitor alone (figure 6G, n=3, p≤0.05). 
ADAM10 expression correlates with poorer 
outcome in a HER2 positive cohort
We showed that the upregulation of ADAM10 levels 
occurred during trastuzumab treatment and upon acquired 
resistance in HER2 positive breast cancer cells. We 
hypothesized that ADAM10 expression might be relevant 
as a biomarker to predict prognosis and trastuzumab 
response in HER2 positive breast cancer patients. 
Therefore we stained tumors from HER2 positive breast 
Figure 7: ADAM10 level is a predictive biomarker for trastuzumab response and is prognostic in a cohort of HER2 
positive breast cancer patients (A) Schematic illustration of the window of opportunity study. HER2 positive breast cancer 
patients received a pre-treatment biopsy and underwent a 21 day trastuzumab (8mg/kg) monotherapy window study before a second biopsy 
was performed. Patients further received 4 cycles of neoadjuvant docetaxel chemotherapy 100 mg/m2 with 6mg/kg trastuzumab q21 prior 
to definitive surgery. (B) Paired tissue samples (pre- and post-treatment) from 5 patients who received trastuzumab monotherapy for 21 
days (as described in A) and from 8 patients (of whom samples of pre- and post-neoadjuvant treatment were available) were stained for 
ADAM10 expression. (C) and (D) Basal ADAM10 expression levels (low or high) of a total of 10 patients (of whom basal biopsies and 
clinical data were available) were correlated with Ki67 staining and tumor size at day 21 and at definitive surgery (ratios between post 
trastuzumab or neoadjuvant treatment vs. pre-treatment). Bar graphs show means ± SD, the differences were assessed by t-Test and a 
p-value is shown (*p≤0.05). (E) Tissue microarrays (TMAs) consisting of tumor core samples from a well annotated HER2 positive breast 
cancer cohort were stained for basal ADAM10 expression by IHC. Relapse-free survival and overall survival of patients were plotted 
according to high or low ADAM10 IRS scores and differences between the groups were assessed using Log-rank test. 
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cancer patients and examples are shown in figure S4A. 
We assessed ADAM10 levels in patients who 
underwent a window study as outlined in figure 7A. The 
characteristics of the patients are listed in table S1. The 
data from paired samples of patient biopsies (5 out of 10 
patients underwent biopsy before and after trastuzumab 
monotherapy treatment) showed that ADAM10 levels 
were significantly increased at day 21 after one dose 
of trastuzumab monotherapy (mean IRS, baseline 0.8, 
95% CI -1.4-3.0 vs. post-treatment 6.8, 95% CI 2.6-
10.9, p ≤ 0.05) (figure 7B, left panel), similar to the cell 
lines and xenograft results. Moreover, compared to low 
basal (= pre-treatment) ADAM10 expression, high basal 
ADAM10 expression was associated with a higher Ki67 
post/pre treatment ratio (high vs. low ADAM expression, 
mean ratio of 1.1, 95% 0.8 to 1.3 vs. 0.7, 95% CI 0.6-0.9 
respectively, p=0.02) and bigger tumor size (high vs. low 
ADAM10 expression, mean post/pre treatment ratio of 
1.2, 95% CI 0.7-1.6 vs. 0.7, 95% CI 0.5-0.9 respectively, 
p=0.02) at day 21 of trastuzumab monotherapy (figure 7C, 
upper and lower panels). 
We also compared basal ADAM10 levels with 
those of the tumors obtained at definitive surgery after 
neoadjuvant chemotherapy and trastuzumab treatment 
(8 paired samples). There also was an overall trend for 
increased ADAM10 expression in the post-neoadjuvant 
treatment samples (figure 7B, right panel). Furthermore, 
pre-treatment ADAM10 levels also predicted higher Ki67 
and poorer clinical response at definitive surgery, although 
these were not statistically significant (figure 7D upper and 
lower panels). 
To assess the potential prognostic value of ADAM10 
levels, we stained a set of consecutive tumor microarrays 
from a cohort of HER2 positive breast cancer patients for 
basal ADAM10 expression. Altogether, tumor samples 
from 69 patients had adequate IHC staining quality 
to be used for survival analysis. The patient and tumor 
characteristics are listed in table S2. Higher ADAM10 
expression was correlated with a statistically significant 
poorer relapse-free survival (RFS) compared to low 
ADAM10 expression (Hazard ratio 5.02, 95% CI 1.41-
17.93 p = 0.006). There was also a trend for a lower overall 
survival although this was not statistically significant 
(Hazard ratio 1.84, 95% CI 0.31-11.03, p = 0.5) (figure 
7E, upper and lower panel). The multivariate analysis 
using known important clinicopathological factors such as 
age, node status, tumor grade, ER status and tumor size, 
suggested that ADAM10 was an independent prognostic 
indicator for RFS (p=0.0024) (table S3A) 
DISCUSSION
Trastuzumab is a standard treatment for HER2 
overexpressing breast and gastric cancer. However, 
primary or acquired resistance remains a major 
drawback. This study and our previous study suggested 
that trastuzumab treatment induced an upregulation 
of ADAM10 and ADAM17 [24], thereby enhancing 
ligand release, maintaining HER member activation and 
counteracting trastuzumab treatment. This was shown 
to be related to PKB inhibition since several inhibitors 
(including a TKI and a PI3K inhibitor) that decrease PKB 
activation induced ADAM10 upregulation. However, the 
increase in ADAM10 level was not in linear relationship to 
PKB inhibition. This indicates that there could be several 
pathways involved in the upregulation of ADAM10, which 
may include the complex crosstalk between PI3K and 
MAPK signaling pathways and possible involvement of 
the FoxO proteins (downstream targets of PKB) [32-34]. 
This is likely to be complicated and will be investigated 
further. It will be of interest to assess whether other HER 
family targeting treatments, such as pertuzumab and 
lapatinib also induce ADAM10 and 17. HER ligands (e.g. 
betacellulin and heregulin) shed by ADAM10 and 17, 
have been shown to mediate resistance to trastuzumab 
[24] and TKI treatment [35]. HB-EGF and BTC were 
associated with poor clinical outcome [36] and combined 
measurement of epigen and neuregulin 4 were predictors 
of relapse free and overall survival in breast cancer 
patients [37]. Therefore, it would be important to study 
further on the interplay between ADAMs with different 
HER ligands and the activation and dimerization status 
of HER receptors [38] in the resistance mechanisms of 
various HER inhibitors in patients.
We showed that naïve and acquired trastuzumab-
resistant cell lines were sensitive to ADAM10 inhibition 
or knockdown through prevention of ligand release 
and inhibition of HER receptor activation. The effect 
of ADAM10 inhibition is similar to those seen when 
inhibiting the tyrosine kinase activities of HER receptors 
by neratinib [39]. Another possible effect of ADAM10 
inhibition is the counteraction of Notch-signalling, 
which has been implicated in trastuzumab resistance [40] 
although this is beyond the scope of this manuscript. We 
showed that the three inhibitors against ADAM10, 17, or 
10/17, equally enhanced trastuzumab response in naïve 
cells but in acquired resistant cells, the dual inhibition 
was superior. However, all these inhibitors may have non-
specific effects on ADAMs and other metalloproteinases 
[41]. We are currently investigating whether other ADAMs 
play a role in mediating trastuzumab resistance. 
Various studies assessed the clinical significance 
of ADAMs. ADAM9 was increased in breast cancer in 
comparison with normal breast tissue and correlated 
positively with HER2 expression [42]. ADAM17 
expression was upregulated in breast cancer compared 
to normal breast tissue and was highest in lymph-node 
metastasis [43]. ADAM10 was upregulated in primary 
liver cancer when compared to normal liver tissue [23]. 
ADAM10 expression in colon cancer enhanced metastasis 
[44] and was associated with chemoresistance [45]. Wang 
et al. (2011) showed that ADAM10 was upregulated in 
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gastric cancer tissue in comparison to normal tissue; higher 
ADAM10 correlated with poorer prognosis and prognostic 
markers [21]. Here we report the first study showing 
the role of ADAM10 in HER2 positive breast cancer. 
ADAM10 expression did not correlate with any known 
prognostic markers. However, trastuzumab treatment led 
to an increase of ADAM10 level in HER2 positive breast 
cancer patients and higher basal ADAM10 expression was 
associated with poorer trastuzumab treatment response 
and relapse-free survival. 
Despite the promising results regarding the role 
of ADAM10 in relation to trastuzumab treatment and 
resistance shown here, there are limitations to our 
study. Since we are interested primarily in the role of 
ADAM10 in acquired trastuzumab resistance, we have 
not investigated its role in a panel of sensitive and innate 
trastuzumab resistant breast cell lines. It will be important 
to assess whether ADAM10 expression could predict 
response in relation to primary trastuzumab resistance 
in a wider panel of breast cell lines with different HER2 
expression. The biopsy samples used in our window 
study could also pose problems if there is intra-tumor 
heterogeneity although the IRS scoring used in this study 
took into account both the percentage and intensity of 
ADAM10 staining. The other limitations are the small 
number of patients used and no statistical plan a priori that 
determined the number of patients in our clinical studies. 
Thus, despite the statistically significant results shown in 
our studies, our work is mainly exploratory and provides 
the hypothesis that ADAM10 expression is a potential 
prognostic and predictive biomarker. We hope to further 
validate ADAM10 as a biomarker using samples from 
randomized controlled trials such as FinHER study [46]
in the future. 
Our study indicated that ADAM10 is a potential 
therapeutic target for HER2 positive breast cancers. 
Friedman et al. reported a phase I/II trial using the 
compound INCB7839, an ADAM10/17 inhibitor, in 
combination with trastuzumab [47]. The overall response 
rate in patients with advanced breast cancer was between 
40% and 55% and the new drug was well tolerated [47]. 
The study also showed that ADAM10/17 inhibitor could 
reduce HER2 cleavage, which is relevant to HER2 
positive patients with tumors expressing p95. We did not 
focus our study on the role of ADAM10 in HER2 cleavage 
in patients’ samples since there is a lack of validity of 
p95 assay and there are controversial reports on the role 
of p95 expression in relation to trastuzumab response 
and resistance [48, 49]. In view of our data showing the 
activities of both ADAM10 and ADAM17 in response 
to trastuzumab, we would support further studies to be 
done to assess the efficacy of ADAM10/17 inhibitor as 
a novel therapy to overcome trastuzumab resistance for 
HER2 positive breast cancer patients. Moreover, the role 
of ADAM10/17 inhibition in addition to the combination 
of anti-HER2 therapies such as trastuzumab with lapatinib 
or pertuzumab should be investigated. 
In summary, we showed that an upregulation of 
ADAM10 level occurred upon trastuzumab treatment 
and resistance. Inhibition or knockdown of ADAM10 
enhanced trastuzumab response in parental cells and 
reversed acquired trastuzumab resistance in HER2 
positive breast cancer cells. For patients who underwent 
trastuzumab monotherapy, trastuzumab treatment 
increased ADAM10 expression and pre-treatment high 
ADAM10 levels predicted poor response to trastuzumab 
at day 21. Moreover, in a cohort of HER2 positive breast 
cancer patients, higher basal ADAM10 expressions were 
correlated with poorer relapse-free survival. Therefore, 
our results indicate that targeting ADAM10 and ADAM17 
might enhance trastuzumab response and overcome 
acquired trastuzumab resistance in HER2 positive breast 
cancer patients. We propose further validation studies to 
confirm ADAM10 level as a prognostic and predictive 
biomarker in HER2 positive breast cancer patients 
undergoing trastuzumab treatment.
MATERIALS AND METHODS
Cell culture
BT474 and SKBR3 cell lines were provided by cell 
services lab at Cancer Research UK (Lincoln’s Inn Fields 
laboratory), which has a stringent quality control in cell 
authenticity and has incorporated short-tandem repeat 
(STR) profiling for cell line validation. Cell culturing 
and the generation of trastuzumab resistant cells were 
described previously [24]. 
ADAM10 IHC scoring
ADAM10 expression level was scored semi-
quantitatively using immunohistochemistry on tumor 
samples based on staining intensity and distribution using 
the immunoreactive score of Remmele and Stegner (IRS) 
[25]. The scoring criteria is a composite score based on 
staining intensity (SI) and percentage of positive cells (PP) 
using the formula IRS = SI × PP. The staining intensity 
(SI) was determined as 0 = negative; 1 = weak; 2 = 
moderate; and 3 = strong and the percentage of positive 
cells (PP) was defined as 0, <1%; 1, 1%–10%; 2, 11%–
50%; 3, 51%–80%; and 4, >80% positive cells. Low 
ADAM10 expression was defined as no or weak staining 
in tumors (IRS of ≤ 1).
Human tissue samples and Immunohistochemistry
Tissue microarrays (TMA) were provided by Oxford 
Radcliffe Biobank in compliance with Human Tissue Act 
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2004 (UK). The window study of HER2 positive breast 
cancer patients was carried out as depicted in figure 7A. 
Tumor size and response were assessed as described [26]. 
Immunohistochemical evaluation was performed for 
HER2, ERα, PgR, and Ki67, as described [27]. The trial 
was conducted at UOM Patologia Mammaria-Az. Instituti 
Ospitalieri di Cremona with appropriate local ethical 
approval (Protocol CE-21392/2012). Paraffin-embedded 
tissues were stained for ADAM10 (Abcam).
Statistical analysis
Prism 6 software (GraphPad software) was used for 
statistical analysis. The differences between two means 
were assessed by t-Test. When investigating one factor, 
one-way ANOVA was used with Bonferroni’s multiple 
comparison. For two factors, two-way ANOVA with 
Tukey’s multiple comparison [28] was used, specifying 
the number of comparisons prior to analysis. Associations 
between the co-variables and ADAM10 level were tested 
by Fisher’s exact test. Overall survival (OS) is defined 
as percentage of patients still alive in the study period 
after diagnosis; and relapse-free survival (RFS) is defined 
as the proportion of patients without relapse (local or 
distant recurrence) during the defined period [29]. The 
multivariate Cox proportional hazards modeling and the 
Kaplan-Meier survival curves analysis were done in R 
statistical environment (v.2.14.1) (R package: survival 
v2.36-14). Tests of statistical significance were two-sided 
and p-values less than 0.05 were considered statistically 
significant in all the above tests. P values are shown (*p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). 
Further details on materials and methods can be 
found in the supplementary method section.
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